cdk7 inhibitor gtaexs617
cdk7 inhibitor gtaexs617: sourced relationships with 1 company · 1 clinical trial tracked.
cdk7 inhibitor gtaexs617 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could cdk7 inhibitor gtaexs617 → RXRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) Advanced solid tumors (including ovarian cancer, colorectal … | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Frequently asked questions
Which companies have sourced relationships with cdk7 inhibitor gtaexs617?
cdk7 inhibitor gtaexs617 has dated SEC/FDA relationship records for RECURSION PHARMACEUTICALS, INC..
How many clinical trials involve cdk7 inhibitor gtaexs617?
BioSniper tracks 1 clinical trial involving cdk7 inhibitor gtaexs617.